Flebogamma DIF
Biological
Grifols Biologicals LLC
Total Payments
$5.5M
Transactions
881
Doctors
19
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $51,705 | 7 | 1 |
| 2023 | $20,515 | 14 | 2 |
| 2022 | $46,467 | 41 | 1 |
| 2020 | $423,205 | 177 | 5 |
| 2019 | $1.3M | 196 | 15 |
| 2018 | $626,735 | 142 | 1 |
| 2017 | $3.0M | 304 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.3M | 724 | 96.4% |
| Travel and Lodging | $105,925 | 87 | 1.9% |
| Consulting Fee | $69,033 | 25 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,616 | 3 | 0.2% |
| Honoraria | $7,462 | 3 | 0.1% |
| Food and Beverage | $4,046 | 39 | 0.1% |
Payments by Type
Research
$5.3M
724 transactions
General
$196,081
157 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD | Grifols Biologicals LLC | $3.9M | 0 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5 DIF in Patients With Post-Polio Syndrome | Grifols Biologicals LLC | $781,649 | 0 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5 DIF in Patients With Post-Polio Syndrome | Grifols Biologicals LLC | $213,002 | 0 |
| Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Liver Failure ACLF at High Risk of Hospital Mortality | Grifols Therapeutics LLC | $203,588 | 0 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5 DIF in Patients With Post-Polio Syndrome | Grifols Therapeutics LLC | $78,917 | 0 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel?Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome | Grifols Therapeutics LLC | $51,189 | 0 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, ParallelGroup Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous Human Flebogamma 5percent DIF in Patients With Post-Polio Syndrome | Grifols Biologicals LLC | $19,868 | 0 |
| A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel?Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome | Grifols Biologicals LLC | $8,945 | 0 |
Top Doctors Receiving Payments for Flebogamma DIF
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $5.3M | 724 |
| , MD | Specialist | Pittsburgh, PA | $64,062 | 39 |
| , MD, PHD | Blood Banking & Transfusion Medicine | Boston, MA | $32,707 | 28 |
| , MD | Neurology | Las Vegas, NV | $27,225 | 18 |
| , MD PHD | Neurological Surgery | Boston, MA | $25,592 | 16 |
| , MD | Rheumatology | Cleveland, OH | $14,334 | 7 |
| , M.D., PHD | Allergy & Immunology | New York, NY | $10,616 | 3 |
| , MD | Allergy & Immunology | Tampa, FL | $5,870 | 2 |
| , MD | Neurology | San Francisco, CA | $4,750 | 2 |
| , MD | Neurology | New York, NY | $3,100 | 2 |
| David Geldmacher | Neurology | Birmingham, AL | $1,725 | 7 |
| , MD | Geriatric Psychiatry | Rochester, NY | $1,151 | 6 |
| Joseph Kiss | Specialist | Pittsburgh, PA | $1,124 | 5 |
| , MD | Geriatric Psychiatry | Saint Louis, MO | $965.31 | 4 |
| , MD | Neurology | Boston, MA | $878.74 | 5 |
| Davangere Devanand | Geriatric Psychiatry | Binghamton, NY | $485.09 | 3 |
| Daniel Kaufer | — | Chapel Hill, NC | $485.09 | 3 |
| , M.D | Neurology | New York, NY | $485.09 | 3 |
| , M.D | Geriatric Psychiatry | New York, NY | $485.09 | 3 |
| , MD | Allergy | San Diego, CA | $40.21 | 1 |
Ad
Manufacturing Companies
- Grifols Biologicals LLC $5.0M
- Grifols Therapeutics LLC $336,168
- Grifols Shared Services North America, Inc. $86,477
- Grifols, S.A. $12,086
Product Information
- Type Biological
- Total Payments $5.5M
- Total Doctors 19
- Transactions 881
About Flebogamma DIF
Flebogamma DIF is a biological associated with $5.5M in payments to 19 healthcare providers, recorded across 881 transactions in the CMS Open Payments database. The primary manufacturer is Grifols Biologicals LLC.
Payment data is available from 2017 to 2024. In 2024, $51,705 was paid across 7 transactions to 1 doctors.
The most common payment nature for Flebogamma DIF is "Unspecified" ($5.3M, 96.4% of total).
Flebogamma DIF is associated with 8 research studies, including "A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD" ($3.9M).